Abstract
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Current Drug Targets
Title:Biologics for Extraintestinal Manifestations of IBD
Volume: 15 Issue: 11
Author(s): Stephan R. Vavricka, Michael Scharl, Martin Gubler and Gerhard Rogler
Affiliation:
Keywords: Arthritis, extraintestinal manifestations, inflammatory bowel disease, uveitis.
Abstract: Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) occur frequently and may present themselves before or after IBD diagnosis. They most commonly affect the eyes, skin, and joints, but can also involve other organs such as the liver. Some EIM are associated with intestinal disease activity and ameliorate by treatment of the underlying IBD. This is seen in patients with peripheral Type 1 arthritis, oral aphthous ulcers, episcleritis, and erythema nodosum. Other EIM are intestinal disease activity-independent such as uveitis, and ankylosing spondylitis. Finally, some EIM (e.g. pyoderma gangrenosum and primary sclerosing cholangitis) may or may not be associated with the underlying IBD. Successful therapy of EIM is important for improving quality of life of IBD patients. TNF antibody therapy is an important treatment option for EIM in IBD patients whereas no such beneficial effect was reported for alpha 4 beta 7 integrin antibodies such as vedolizumab so far. This article reviews the therapeutic experience with TNF antibodies for the treatment of EIM in IBD patients.
Export Options
About this article
Cite this article as:
Vavricka R. Stephan, Scharl Michael, Gubler Martin and Rogler Gerhard, Biologics for Extraintestinal Manifestations of IBD, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140908125453
DOI https://dx.doi.org/10.2174/1389450115666140908125453 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treat to Target in Spondyloarthritis: The Time has Come
Current Rheumatology Reviews Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Phage Display Derived Therapeutic Antibodies
Current Pharmaceutical Biotechnology Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals p53 Peptide Prevents LITAF-Induced TNF-Alpha-Mediated Mouse Lung Lesions and Endotoxic Shock
Current Molecular Medicine Hypovitaminosis D in Patients with Ankylosing Spondylitis: Frequency and Consequences
Current Rheumatology Reviews Intestinal Microbiota: A Regulator of Intestinal Inflammation and Cardiac Ischemia?
Current Drug Targets Inflammatory Mediators as Potential Therapeutic Targets in the Spine
Current Drug Targets - Inflammation & Allergy Anti-Tumor Necrosis Factor-α Therapy in Undifferentiated Spondyloarthritis (USpA)
Current Rheumatology Reviews The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions
Current Drug Targets The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue
CNS & Neurological Disorders - Drug Targets No Association of MicroRNA-146a rs2910164 Polymorphism and Risk of Primary Gout Development in Chinese Han Populations: A Case-control Study
Current Rheumatology Reviews Genetics of Spondyloarthropathies and Inflammatory Bowel Disease: Searching for Common Susceptibility Factors
Current Rheumatology Reviews Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets Periodontal Pathogens are Likely to be Responsible for the Development of Ankylosing Spondylitis
Current Rheumatology Reviews Rheumatic Manifestations Associated with Inflammatory Bowel Diseases
Current Rheumatology Reviews Natural Inhibitors against Potential Targets of Cyclooxygenase, Lipoxygenase and Leukotrienes
Combinatorial Chemistry & High Throughput Screening Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews